|
Aug 08, 2022
|
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
|
|
Aug 04, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Aug 03, 2022
|
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
|
|
Jul 29, 2022
|
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
|
|
Jul 26, 2022
|
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
|
|
Jul 14, 2022
|
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
|
|
Jul 13, 2022
|
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
|
|
Jul 07, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Jun 29, 2022
|
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
|
|
Jun 16, 2022
|
NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease
|
|
Jun 13, 2022
|
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
|
|
Jun 10, 2022
|
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
|
|
Jun 06, 2022
|
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
|
|
Jun 06, 2022
|
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
|
|
Jun 02, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Jun 01, 2022
|
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
|
|
May 12, 2022
|
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
|
|
May 05, 2022
|
GBT Announces New Employment Inducement Grants
|
|
May 05, 2022
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
May 04, 2022
|
GBT Reports First Quarter 2022 Financial Results
|
|
Apr 28, 2022
|
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
|
|
Apr 27, 2022
|
GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
|
|
Apr 07, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Mar 24, 2022
|
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
|
|
Mar 10, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Mar 03, 2022
|
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
|
|
Feb 28, 2022
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
Feb 23, 2022
|
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
|
|
Feb 16, 2022
|
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
|
|
Feb 16, 2022
|
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
|
|
Feb 03, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Jan 27, 2022
|
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
|
|
Jan 10, 2022
|
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
|
|
Jan 06, 2022
|
GBT Announces New Employment Inducement Grants
|
|
Jan 04, 2022
|
GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
|